Antiangiogenic cancer drug drives lymphangiogenic metastasis

Area of Science:

• Oncology
• Cancer Biology
• Vascular Biology

Background:

• Tumor vasculature is a key target for anti-cancer therapies.
• Disrupting tumor blood supply can inhibit tumor growth.
• The role of tumor lymphatics in treatment response is complex and not fully understood.

Purpose of the Study:

• To investigate the effects of a tumor blood vessel-destroying drug on lymphatic vessel development.
• To determine if induced lymphatics impact treatment efficacy.
• To understand the mechanisms by which tumor lymphatics may contribute to treatment failure.

Main Methods:

• Utilized preclinical cancer models treated with a vascular-disrupting agent.
• Assessed tumor lymphatic vessel density and function using immunohistochemistry and imaging techniques.
• Evaluated tumor growth and treatment response in the presence of induced lymphatics.

Main Results:

• Treatment with the vascular-disrupting agent led to a significant increase in tumor lymphatic vessel density.
• The newly developed lymphatics were functional and associated with increased interstitial fluid pressure.
• Enhanced lymphatic development correlated with reduced drug penetration and accelerated tumor regrowth, indicating treatment failure.

Conclusions:

• Vascular-disrupting cancer drugs can paradoxically stimulate the formation of tumor lymphatics.
• These induced lymphatics can impair drug delivery and promote tumor escape.
• Targeting both tumor vasculature and lymphatics may be necessary for effective cancer therapy.